The FDA has proposed excluding weight-loss drugs, such as Ozempic/Wegovy and Zepbound from a key compounding list, ...

On May 1, the US Food and Drug Administration (FDA) announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the ...

The US Food and Drug Administration (FDA) on Tuesday released a warning letter sent to Orange, CA-based distributor NuCare Pharmaceuticals after the company failed to correct certain drug listings.

On April 16, 2026, the U.S. Food & Drug Administration (FDA) announced it will convene the Pharmacy Compounding Advisory Committee (PCAC) on July ...

The FDA said Walgreens has addressed violations related to drug listing deficiencies for one of its products, according to a Dec. 19 close-out letter. The agency previously cited Walgreens in ...

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear ...

The Food and Drug Administration proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list.

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug shortage ...

The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The Food and Drug Administration removed the black box warning from hormone replacement therapies late last year, and ...